ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Sjögren’s syndrome"

  • Abstract Number: 0777 • ACR Convergence 2024

    Rheumatoid Factor B Cell Clones Proliferate Predominantly as Atypical Memory B Cells in Reactive Cervical Lymph Node Follicles Compared to Extrafollicular Sites in Affected Salivary Glands of SjS Patients

    Theodoros Ioannis Papadimitriou1, Jing Jing Wang2, Xuehui He3, Sidney van der Zade4, Massis Krekorian5, Prashant Singh6, Erik Dik5, Ger Pruijn5, Tom Gordon2, Hans Koenen7, Martijn Huijnen8 and Rogier Thurlings1, 1Radboudumc, Department of Rheumatology, Nijmegen, Gelderland, Netherlands, 2Flinders University, Adeleide, Australia, 3Radboudumc, Nijmegen, Netherlands, 4Radboudumc, Amsterdam, Netherlands, 5Radboudumc, Nijmegen, Gelderland, Netherlands, 6Radboudumc, Department of Medical BioSciences, Nijmegen, Netherlands, 7Radboudumc, Department of Medical Immunology, Nijmegen, Gelderland, Netherlands, 8Radboudumc, Department of Medical BioSciences, Nijmegen, Gelderland, Netherlands

    Background/Purpose: Sjögren’s syndrome (SjS) is a chronic inflammatory disorder, characterized by formation of autoantibodies. Over time rheumatoid factor (RF) clones can give rise to cryoglobulinemic…
  • Abstract Number: 1415 • ACR Convergence 2024

    Metformin Improves Salivary Gland Infiltration and Objective Measures of Dry Eyes in Sjögren’s Disease: A Retrospective Observational Study

    Astrid Rasmussen1, Alan Baer2, Thomas Grader-Beck3, Margaret Beach4, Blake M. Warner5, Christopher Lessard1, A. Darise Farris1 and Robert Hal Scofield1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Johns Hopkins, Baltimore, MD, 4NIH/NIDCR, Arlington, VA, 5National Institutes of Health, Bethesda, MD

    Background/Purpose: Metformin (Met) is a widely used, first-line antidiabetic drug with AMPK-dependent anti-inflammatory and immunomodulatory effects. In in vitro studies and human trials in SLE…
  • Abstract Number: 1432 • ACR Convergence 2024

    Diagnostic Performance of Mayor Salivary Gland Ultrasound for Diagnosis of Sjögren’s Syndrome in Routine Clinical Practice

    Carmen Raya-Santos1, José Miguel Senabre2, José Antonio Bernal3, Rocío Gallego Campuzano4, Lara Pons-Canet2, Ana Pons-Bas2, Juan Carlos Cortes4, Gregorio Santos-Soler5 and José Rosas-Gómez de Salazar6, 1Hospital Marina Baixa, Villajoyosa (Alicante), Spain, 2Hospital Marina Baixa, Villajoyosa, Spain, 3Hospital Marina Baixa (Villajoyosa), Alicante, Spain, 4Hospital Marina Baixa, Villajoyosa, Comunidad Valenciana, Spain, 5Hospital Marina Baixa, Villajoyosa, 6Hospital Marina Baixa, PALMA DE MALLORCA, Comunidad Valenciana, Spain

    Background/Purpose: Major salivary glands ultrasound (SGU) is a promising tool in the diagnosis of Sjögren syndrome (SS) and has demonstrated good sensitivity and specificity in…
  • Abstract Number: 2293 • ACR Convergence 2024

    Altered Expression of the MicroRNA Biogenesis Machinery Components Correlates with Inflammatory Parameters in Salivary Glands of Patient with Sjögren’s Disease

    Sergio Aguilera1, Patricia Carvajal2, Isabel Castro2, María-José Barrera3, Sergio González4, Claudio Molina3 and María-Julieta González2, 1Clinica Indisa, Santiago, Chile, 2Universidad de Chile, Santiago, Chile, 3Universidad San Sebastián, Santiago, Chile, 4Universidad Mayor, Santiago, Chile

    Background/Purpose: MicroRNAs (miRNAs) are small non-coding RNAs involved in the regulation of gene expression at the post-transcriptional level (by translational blocking or mRNA degradation). The…
  • Abstract Number: 2309 • ACR Convergence 2024

    Damage Accrual Predicts the Development of Lymphoma in Primary Sjogren’s Syndrome

    Ana Mafalda Abrantes1, Pedro Gaspar2 and David Isenberg3, 1Internal Medicine Department, Hospital Santa Maria, Unidade Local de Saúde Santa Maria, Lisbon, Portugal, Lisbon, Portugal, 2Internal Medicine Department, Hospital Santa Maria, Unidade Local de Saúde Santa Maria, Lisbon, Portugal, Povoa de Santa Iria, Portugal, 3University College London, London, United Kingdom

    Background/Purpose: Primary Sjogren Syndrome (pSS) is an autoimmune disease affecting primarily exocrine glands. Over a quarter of patients have systemic involvement, which includes the development…
  • Abstract Number: 0889 • ACR Convergence 2024

    Unraveling the Progression of Sjögren’s Disease at the Cellular and Histological Level Using Single-cell and Spatial Transcriptomics

    Tomás Gomes1, Matilde Bandeira2, Rui do Amaral Vieira1, Bianca Correia1, Sofia Barreira3, Pedro Gaspar4, Rita Cruz-Machado5, Beatriz Filipe1, Pedro Ávila-Ribeiro1, Filipa Ribeiro1, Bruno Vidal1, Beatriz Val1, Filipa Costa6, Ana Teodósio Chícharo7, Augusto Silva1, Manuel Silvério-Antonio1, João Forjaz Lacerda1, João Eurico Fonseca1, Dolores López Presa8, Nikita Khmelinskii1, Saumya Kumar9, Luis Graca1 and Vasco C. Romão10, 1Instituto de Medicina Molecular (iMM Lisboa), Lisboa, Portugal, 2Centro Hospitalar Universitario Lisboa Norte, Lisboa, Portugal, 3Unidade Local de Saúde Santa Maria, Serviço de Reumatologia e Doenças Ósseas Metabólicas, Lisboa, Portugal, Lisbon, Portugal, 4Internal Medicine Department, Hospital Santa Maria, Unidade Local de Saúde Santa Maria, Lisbon, Portugal, Povoa de Santa Iria, Portugal, 5Unidade Local de Saúde Santa Maria, Serviço de Reumatologia e Doenças Ósseas Metabólicas, Lisboa, Portugal, Lisboa, Portugal, 6Rheumatology Department, Unidade Local de Saúde de Santa Maria. Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Lisbon, Portugal, 7Unidade Local de Saúde do Algarve, Hospital de Faro, Faro, Portugal, Faro, Portugal, 8Pathology Department, Unidade Local de Saúde de Santa Maria, Lisbon Academic Medical Centre, Lisboa, Portugal, 9TWINCORE, a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany, Hannover, Germany, 10Rheumatology Department, ULS Santa Maria & Rheumatology Research Unit, Instituto Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal

    Background/Purpose: Sjögren’s Disease (SjD) is a systemic autoimmune disease that primarily targets salivary and lacrimal glands, causing tissue deterioration and loss of function. Disease progression…
  • Abstract Number: 1416 • ACR Convergence 2024

    Ultrasound (US)-guided Core-needle Biopsy (CNB) of the Non-swollen Parotid Gland: A Feasible and Well-tolerated Technique for Diagnosing and Stratifying Sjögren’s Disease (SjD)

    Helena Achten1, Eva Genbrugge2, David Creytens2, Amber Vanhaecke3, Kristel De Boeck2, Dirk Elewaut4 and Isabelle Peene2, 1Ghent University, Merelbeke, Belgium, 2Ghent University, Ghent, Belgium, 3Ghent University, Ghent, Oost-Vlaanderen, Belgium, 4Ghent University and VIB Center for Inflammation Research, Ghent, Belgium

    Background/Purpose: Histopathology remains a cornerstone in the diagnostic workup of Sjögren’s disease (SjD). Ultrasound (US)-guided core needle biopsy (CNB) of the parotid gland has emerged…
  • Abstract Number: 1652 • ACR Convergence 2024

    Extracellular Vesicles from Lymphocyte B and Neutrophil Presents Ro52, Ro60 and La Autoantigens in Patient Suffering from Sjögren Syndrome

    Lily BRUYERE1, Anne-Claire DUCHEZ2, Martin KILLIAN3 and Stéphane PAUL4, 1université jean-monnet, saint-etienne, 2EFS, saint-etienne, 3chu Saint-Etienne, saint-etienne, 4CIRI, Saint Etienne, France

    Background/Purpose: Extracellular Vesicles (EVs) are double lipid bilayer-enclosed membranous vesicles, produced and discharged from almost all cells. EVs are known for inter-cellular communication by releasing…
  • Abstract Number: 2294 • ACR Convergence 2024

    Pharmacodynamic Effects of Nipocalimab on Disease Biomarkers in Patients with Moderate-to-Severe Active Sjögren’s Disease: Results from a Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2 Study

    Kathy Sivils1, Steven Leonardo2, He Li3, Keying Ma4, Matthew J. Loza5, Jonathan J. Hubbard4, Kim Campbell4 and Sheng Gao4, 1Johnson & Johnson Innovative Medicine, Edmond, OK, 2Janssen Research & Development, LLC, a Johnson & Johnson Company, Cambridge, MA, 3Janssen Research & Development, LLC, Therapeutics Discovery, Spring House, PA, 4Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, 5Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, USA, Spring House, PA

    Background/Purpose: Nipocalimab is a fully human, immunoglobulin G (IgG) 1 monoclonal antibody that selectively binds to the IgG-binding site of the neonatal crystallizable fragment receptor…
  • Abstract Number: 2310 • ACR Convergence 2024

    Prospective Evaluation of Pulmonary Involvement in Patients with Primary Sjögren’s Disease, Using Pulmonary Function Tests and High Resolution Computed Tomography, Reveals High Prevalence of Subclinical Interstitial Lung Disease, Along with Small Airways Disease

    Panagiotis Panagopoulos1, Loukas chatzis2, Eirini Chatzinikita3, Katerina Malagari4, Theodoros Vassilakopoulos3, Athanasios Tzioufas5 and Andreas Goules6, 1Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, 2Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Cholargos Athens, Greece, 3Department of Physiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, 42nd Department of Radiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, 5LAIKO HOSPITAL, Athens, Greece, 6GENERAL HOSPITAL LAIKO ATHENS, Athens, Greece

    Background/Purpose: Interstitial lung disease (ILD) and small airways disease (SAD) are frequent pulmonary manifestations of primary Sjögren’s disease (SjD). The relation between these two entities…
  • Abstract Number: 0892 • ACR Convergence 2024

    Peptides from Candidate Sjögren’s Disease Autoantigens and Salivary Gland Tissue-Enriched Proteins Eluted from Human Salivary Gland HLA-DR

    Tommi C. Taylor1, Sri Ramarathinam2, Shan Zou Chung2, Kirti Pandey2, Ananth Aditya Jupudi1, Bhuwan Khatri3, Sherri Longobardi3, Charmaine Lopez-Davis3, Astrid Rasmussen3, Kiely Grundahl3, Robert Hal Scofield3, Christopher Lessard3, Linda F. Thompson3, Anthony W. Purcell2 and A. Darise Farris3, 1University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2Monash University, Clayton, Victoria, Australia, 3Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Sjögren’s Disease (SjD) is characterized by aberrant autoimmune reactions in lacrimal and salivary glands (SG) leading to severe dryness. Evidence for B cell help…
  • Abstract Number: 1417 • ACR Convergence 2024

    Organ-Specific Autoimmune Involvement in Primary Sjögren’s Disease

    Gabriela Hernández-Molina and Ariel Garcia-Torralba, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    Background/Purpose: To assess the presence of organ-specific autoimmune diseases in a cohort of patients with primary Sjögren’s Disease (SjD).Methods: We retrospectively reviewed the records of…
  • Abstract Number: 1687 • ACR Convergence 2024

    IgG and IgA anti-LIN28A Outperform Anti-dsDNA and anti-Sm in Distinguishing SLE from Health and Other Autoimmune Diseases

    Ioannis Parodis1, Dionysis Nikolopoulos2, Julius Lindblom3, Denis Lagutkin3, Lorenzo Beretta4, Maria Orietta Borghi5, Janique Peyper6, Guillermo Barturen7, Per-Johan Jakobsson3, Marta Alarcon-Riquelme8, Natalia Sherina3 and Helena Idborg9, and PRECISESADS Clinical Consortium, 1Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, 2Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, 3Karolinska Institutet, Stockholm, Sweden, 4Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy, 5Università degli Studi di Milano Statale, Milano, Italy, 6Sengenics Corporation Pte Ltd, Singapore, Singapore, 7Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, 8Fundación Progreso y Salud, Andalusian Government, Granada, Spain, 9Karolinska Institutet, Solna, Sweden

    Background/Purpose: Systemic lupus erythematosus (SLE) is characterised by the production of a multitude of autoantibodies (abs). The diagnosis of SLE is supported by the presence…
  • Abstract Number: 2295 • ACR Convergence 2024

    Association of Early Markers in Patients with Sjögren’s Syndrome in a Diverse Academic Cohort

    Danielle Henry1 and Schartess Culpepper Pace2, 1University of Miami at Holy Cross Health, Fort Lauderdale, FL, 2University of Miami, Pembroke Pines, FL

    Background/Purpose: Sjogren’s syndrome (SS) is a heterogenous systemic inflammatory autoimmune disease characterized by sicca symptoms. It affects 0.3-1 per 1000 of the general population1. Studies…
  • Abstract Number: 2524 • ACR Convergence 2024

    Metabolite Profiling of Saliva for the Discrimination of Behcet’s Disease, Sjogren’s Syndrome, and Recurrent Aphthous Stomatitis

    Sooah Kim1, Ye Ji Jung2, Joong Kyong Ahn3 and Jiwon Hwang4, 1Environment Science & Biotechnology, Jeonju University, Jeonju, Republic of Korea, 2Division of Rheumatology, Department of Internal Medicine, Kyung Hee University Hospital, Seoul, Republic of Korea, 3Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, 4Internal Medicine, Kyung Hee University Hospital, Seoul, Republic of Korea

    Background/Purpose: Oral manifestations can be the initial indicators of systemic diseases such as Behcet’s disease (BD) and Sjogren’s syndrome (PSS). The frequency and presentation of…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 24
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology